Total
0
Shares
Zoono Group (ASX:ZNO) - Managing Director & CEO, Paul Hyslop - The Market Herald
Managing Director & CEO, Paul Hyslop
Source: Zoono Group
  • Zoono Group's (ZNO) Z-71 Microbe Shield surface sanitiser has been successfully tested against COVID-19
  • Laboratory tests show the product is more than 99.99 per cent effective against the virus
  • Z-71 is the same technology used in the company's hand sanitiser
  • Zoono's products are known to protect humans against a variety of viruses for up to 30 days on surfaces and 24 hours on hands
  • Zoono is up 9.26 per cent on the market this morning, trading at $1.77 per share

Zoono Group's (ZNO) Z-71 Microbe Shield surface sanitiser has been successfully tested against the recent coronavirus (COVIOD-19).

Laboratory tests show the product is more than 99.99 per cent effective against the virus.

COVID-19 has become a global concern and has been shown to survive on surfaces for up to nine days. Zoono products have been successfully tested against a variety of pathogens for up to 30 days on surfaces and 24 hours on hands.

Z-71 was previously tested against bovine coronavirus, however, this latest strain required new testing.

The company conducted two separate tests to EN Standard 14476:2013+A2:2019 for chemical disinfectants and antiseptics.

EN14476 is the European Standard that applies to products within the medical area, this includes hygienic hand rubs, hygienic hand wash, instrument disinfection by immersion, surface disinfection by wiping, spraying, flooding and others.

Z-71 Microbe Shield is the same technology used in the company's hand sanitisers.

"Zoono is very pleased with the results which further demonstrates the ability of the Zoono technology to be part of the solution to prevent and protect against the spread of the COVID19 Virus," the company told the market.

Zoono is up 9.26 per cent on the market this morning, trading at $1.77 per share at 11:31 am AEDT.


Subscribe


ZNO by the numbers
More From The Market Herald
Cleanspace (ASX: CSX) - CEO, Dr Alex Birrell - The Market Herald

" CleanSpace (ASX:CSX) shares soar on ASX listing

CleanSpace (CSX) has today listed on the Australian Securities Exchange (ASX) with an initial market capitalisation of $339.7 million.
PainChek (ASX:PCK)- CEO, Philip Daffas (left) - The Market Herald

" PainChek (ASX:PCK) signs partnership deal with disability service provider

PainChek (PCK) has signed its first partnership with a disability service provider Nulsen Group.
Proteomics International Laboratories (ASX:PIQ) - Managing Director, Dr Richard Lipscombe - The Market Herald

" Proteomics International (ASX:PIQ) to raise $6M for high-tech blood test

Proteomics International (PIQ) has received firm commitments to undertake a $6 million share placement.
Immutep (ASX:IMM) - CEO, Marc Voigt - The Market Herald

" Immutep’s (ASX:IMM) efti drug to be tested against COVID-19

A novel cancer immunotherapy developed by Immutep (IMM) will be tested in an investigator-initiated clinical trial against COVID-19.